Antiphospholipid syndrome primary prevention

Jump to navigation Jump to search

Antiphospholipid syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Antiphospholipid syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Antiphospholipid syndrome primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Antiphospholipid syndrome primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Antiphospholipid syndrome primary prevention

CDC on Antiphospholipid syndrome primary prevention

Antiphospholipid syndrome primary prevention in the news

Blogs on Antiphospholipid syndrome primary prevention

Directions to Hospitals Treating Antiphospholipid syndrome

Risk calculators and risk factors for Antiphospholipid syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

Overview

Primary Prevention

The primary prevention of antiphospholipid syndrome is as follows:[1][2][3]

  • Anticoagulation in patients with risk factors for arterial and venous thrombosis.
  • Minimizing the contribution of reversible risk factors for recurrent thrombosis.
  • A daily low dose of aspirin for primary thrombosis prevention in asymptomatic individuals with persistent antiphospholipid antibodies.

Patients with definite antiphospholipid syndrome and first venous event* Patients with definite antiphospholipid syndrome and recurrent events despite warfarin with a target intensity of 2·0–3·0 Patients with arterial thrombosis with single positive or low-titre antiphospholipid antibodies Secondary prophylaxis Indefinite anticoagulation to a target INR 2·0–3·0 Indefinite anticoagulation to a target INR 3·0–4·0 or alternative therapies such as extended therapeutic dose low-molecular-weight heparin As per usual recommendations for arterial thrombosis Patients with definite antiphospholipid syndrome and arterial event* Indefinite anticoagulation to a target INR 3·0–4·0 or combined antithrombotic treatment Patients with venous thromboembolism with single positive or low-titre antiphospholipid antibodies As per usual recommendations for deep vein thrombosis treatment INR=international normalised ratio. *Less aggressive or long-lasting antithrombotic treatments might be appropriate in low-risk patients.

References

  1. Nalli C, Andreoli L, Casu C, Tincani A (2014). "Management of recurrent thrombosis in antiphospholipid syndrome". Curr Rheumatol Rep. 16 (3): 405. doi:10.1007/s11926-013-0405-4. PMID 24449256.
  2. Erkan D, Lockshin MD (2004). "How much warfarin is enough in APS related thrombosis?". Thromb Res. 114 (5–6): 435–42. doi:10.1016/j.thromres.2004.06.010. PMID 15507275.
  3. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR (1995). "The management of thrombosis in the antiphospholipid-antibody syndrome". N Engl J Med. 332 (15): 993–7. doi:10.1056/NEJM199504133321504. PMID 7885428.

Template:WH Template:WS